Skip to content

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Sattva Swarup Neelapu, Frederick Lundry Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David Bernard Miklos, Caron Alyce Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, Andre Henri Goy, Brian Thomas Hill, Mitchell Reed Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier L Munoz, Irit Mazza Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas Elmer Witzig, Patrick Michael Reagan, Adrian I Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff S. Aycock, Meg Elias, David D. Chang, Jeff Wiezorek, William Y. Go

New England Journal of Medicine · 2017 · 6,172 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A. H., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., … Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. New England Journal of Medicine, 377(26), 2531–2544. https://doi.org/10.1056/nejmoa1707447

In text: (Neelapu et al., 2017)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy. METHODS: anti-CD19 CAR T cells per kilogram of body weight after receiving a conditioning regimen of low-dose cyclophosphamide and fludarabine. The primary end point was the rate of objective response (calculated as the combined rates of complete response and partial response). Secondary end points included overall survival, safety, and biomarker assessments. RESULTS: Among the 111 patients who were enrolled, axi-cel was successfully manufactured for 110 (99%) and administered to 101 (91%). The objective response rate was 82%, and the complete response rate was 54%.With a median follow-up of 15.4 months, 42% of the patients continued to have a response, with 40% continuing to have a complete response. The overall rate of survival at 18 months was 52%. The most common adverse events of grade 3 or higher during treatment were neutropenia (in 78% of the patients), anemia (in 43%), and thrombocytopenia (in 38%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 13% and 28% of the patients, respectively. Three of the patients died during treatment. Higher CAR T-cell levels in blood were associated with response. CONCLUSIONS: In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. (Funded by Kite Pharma and the Leukemia and Lymphoma Society Therapy Acceleration Program; ZUMA-1 ClinicalTrials.gov number, NCT02348216 .).

  1. Integrated analysis of multimodal single-cell data2021
  2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
  3. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
  4. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer2012
  5. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986

Metadata from OpenAlex (CC0). Citations are generated from the published record.